Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Incidence of cardiac events associated with next-generation bruton tyrosine kinase (BTK) inhibitors compared to control in hematologic malignancies: A meta-analysis of randomized trials

View Full Paper
Ask AI
Bookmark
Share

Authors

JTJason TaSASalman AhmadSASamir A. Afifi

Discussion

Loading...

Member takes

Overview

Meta-analysis finds next-generation BTK inhibitors elevate atrial fibrillation risk in hematologic malignancies, indicating a need for careful cardiac monitoring.

Key Points

  • Next-generation BTK inhibitors are linked to higher any-grade cardiac events compared to control, with a rate of 15.2%.
  • The analysis included seven RCTs and over 3,200 patients, finding increased incidences of atrial fibrillation at 3.7%.
  • Risk ratios were calculated for cardiac events with confidence intervals, utilizing random-effects models during meta-analysis.
  • Vigilance for cardiac effects in patients is crucial, especially regarding atrial arrhythmias and underlying cardiovascular risks.

Cite This Study

Ta et al. (2025) studied this question.

synapsesocial.com/papers/69362f6e4fa91c937236e0d2https://doi.org/10.1182/blood-2025-8067
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Incidence of bleeding and hypertension in patients with hematologic malignancies treated with next-generation Bruton tyrosine kinase (BTK) inhibitors: A meta-analysis of randomized controlled trials2025
  2. 2Atherosclerotic cardiovascular events associated with BTK inhibitors: a systematic review and meta-analysis of harms2025
  3. 3Cardiovascular Safety of Bruton Tyrosine Kinase Inhibitors: From Ibrutinib to Next-Generation Agents2025 · 12 citations
  4. 4Number of patients needed to treat to prevent one atrial fibrillation event with zanubrutinib versus ibrutinib and acalabrutinib in B-cell malignancies2025
  5. 5PO50 | Treatment with BTK inhibitors in patients affected by chronic lymphocytic leukemia: safety and hemostasis2025